Integration of Multi-omics Data Based on Deep Learning for Subtyping of Low-Grade Glioma.

Journal: Journal of molecular neuroscience : MN
Published Date:

Abstract

Low-grade gliomas (LGGs) represent a complex and aggressive category of brain tumors. Despite recent advancements in molecular subtyping and characterization, the necessity to identify additional molecular subtypes and biomarkers remains. To delineate survival subtypes in LGG, we propose a deep learning (DL)-based multi-omics SurvivalNet (MOST) model. By integrating histological RNA-seq, miRNA-seq, and DNA methylation data obtained from The Cancer Genome Atlas (TCGA), we applied the MOST model to analyze data from 497 LGG patients. We employed consensus clustering to reveal heterogeneous subtypes, validated our findings using an internal validation set through a supervised classification algorithm, and further evaluated the robustness of our model in an independent external cohort. The DL-based MOST model identified two optimal patient subtypes with significant differences in survival (P = 3.07E - 16) and demonstrated a robust model fit (C = 0.92 ± 0.02). This multi-omics model was validated using external Chinese Glioma Genome Atlas (CCGA) datasets, including RNA-Seq (N = 497, C = 0.85), miRNA array (N = 89, C = 0.80), and DNA methylation (N = 89, C = 0.61). High-risk subcategories exhibited increased expression of the homeobox (HOX) family genes, regulation of cholesterol homeostasis, glycolysis, epithelial-mesenchymal transition pathway enrichment, and a high density of M2 macrophages. Our study utilized deep learning to identify multi-omics features associated with differential survival outcomes in patients with LGG. This work is anticipated to significantly enhance prognosis prediction for LGG due to its robustness within the cohorts.

Authors

  • Huilin Li
    Department of Ophthalmology, Heji Hospital Affiliated with Changzhi Medical College, Changzhi, China.
  • Musu Li
    Department of Biostatistics, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
  • Yue Sun
    Department of Rheumatology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China.
  • Er Yu
    School of Public Affairs, Institute of Land Science and Property, Zhejiang University, Hangzhou, 310058, China.
  • Jiahe Pan
    Department of Social Security, School of Health Police and Management, Nanjing Medical University, Nanjing, 211166, China.
  • Yiwen Wu
    School of Information Engineering and Artifical Intelligence, Lanzhou University of Finance and Economics, Lanzhou 730020, Gansu, China. Electronic address: 2516482760@qq.com.
  • Zixuan Lu
    School of Computer Science and Technology, Heilongjiang University, Harbin 150080, China.
  • Hongmei Wo
    Department of Social Security, School of Health Police and Management, Nanjing Medical University, Nanjing, 211166, China.
  • Fang Shao
    Department of Biostatistics, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
  • Dongfang You
    Department of Biostatistics, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
  • Shaowen Tang
    Department of Epidemiology, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Yang Zhao
    The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Juncheng Dai
    Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, No. 101, Longmian Avenue, Nanjing, 211166, Jiangsu, China.
  • Honggang Yi
    Department of Biostatistics, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, 211166, China. honggangyi@njmu.edu.cn.